Search

Your search keyword '"Privitera AC"' showing total 9 results
Start Over Author "Privitera AC" Database OpenAIRE
9 results on '"Privitera AC"'

1. Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy

Author

Vitello, A, Grova, M, Pugliese, D, Rizzello, F, Lanzarotto, F, Lavagna, A, Caccaro, R, Cappello, M, Viola, A, Ribaldone, Dg, Principi, M, Stasi, E, Scribano, Ml, Maida, M, Soriano, A, Bezzio, C, Bodini, G, Mocciaro, F, Privitera, Ac, Simondi, D, Giuffrida, E, D'Incà, R, Ricci, C, Gionchetti, P, Armuzzi, A, Orlando, A, Daperno, M, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD, Vitello A., Grova M., Pugliese D., Rizzello F., Lanzarotto F., Lavagna A., Caccaro R., Cappello M., Viola A., Ribaldone D.G., Principi M., Stasi E., Scribano M.L., Maida M., Soriano A., Bezzio C., Bodini G., Mocciaro F., Privitera A.C., Simondi D., Giuffrida E., D'Inca R., Ricci C., Gionchetti P., Armuzzi A., Orlando A., and Daperno M.

Subjects
musculoskeletal diseases, Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Effectiveness, Young Adult, Internal medicine, Adalimumab, Medicine, Humans, Adverse effect, skin and connective tissue diseases, Colectomy, Aged, Retrospective Studies, Real-world evidence, Hepatology, business.industry, Gastroenterology, Effectivene, Retrospective cohort study, Induction Chemotherapy, Middle Aged, medicine.disease, Ulcerative colitis, Discontinuation, Clinical Practice, Treatment Outcome, Italy, Safety, Concomitant, Colitis, Ulcerative, Female, Tumor Necrosis Factor Inhibitors, business, medicine.drug
Abstract

Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.0%). At week 8, clinical responses were observed in 177 cases (46.5%) and clinical remission in 136 cases (35.7%). At 12 months, remission was observed in 128 cases (33.6%). Overall, 44 patients required colectomy, and 170 patients (44.6%) were still taking adalimumab when data were collected. Variables associated with adalimumab discontinuation were concomitant steroid treatment, severe clinical-endoscopic activity at baseline, need for adalimumab intensification and drug-related adverse events. Variables associated with colectomy were concomitant steroid treatment and high baseline C-reactive protein. Conclusion Adalimumab is safe and effective for the treatment of ulcerative colitis.

Published
2021

2. Two years Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

Author

Pugliese, D, Privitera, G, Rogai, F, Variola, A, Viola, A, Laterza, L, Privitera, Ac, Allocca, M, Bossa, F, Cappello, M, Daperno, M, Lorenzon, G, Mazzuoli, S, Principi, M, Sablich, R, Moser, L, Ferronato, A, Traini, S, Tapete, G, Bodini, G, Di Girolamo, M, Grossi, L, Mocci, G, Ricci, C, Saibeni, S, Festa, S, Spagnuolo, R, Cortelezzi, Cc, Mocciaro, F, Rizzello, F, Armuzzi, A, and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD

Subjects
remission, naïve, persistence, Golimumab, ulcerative colitis
Published
2021

3. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

Author

Fabio Salvatore Macaluso, Gaetano Inserra, Marco Ventimiglia, Maria Cappello, Mario Cottone, Antonio Carroccio, Angela Alibrandi, Antonino Carlo Privitera, Walter Fries, Filippo Mocciaro, N. Belluardo, A. Magnano, Sara Renna, S. Siringo, S. Garufi, Serena Porcari, C. Ferracane, Ambrogio Orlando, Alessandro Vitello, C. Bertolami, Oriana Fidanza, Roberto Di Mitri, Anna Viola, G. Magrì, and Porcari S, Viola A, Orlando A, Privitera AC, Ferracane C, Cappello M, Vitello A, Siringo S, Inserra G, Magnano A, Mocciaro F, Di Mitri R, Belluardo N, Fidanza O, Garufi S, Magrì G, Bertolami C, Carroccio A, Macaluso FS, Renna S, Ventimiglia M, Alibrandi A, Cottone M, Fries W

Subjects
Adult, Male, medicine.medical_specialty, Settore MED/09 - Medicina Interna, Drug-Related Side Effects and Adverse Reactions, Kaplan-Meier Estimate, Anti-Tumour Necrosis Factor, Disease, Inflammatory bowel disease, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Internal medicine, medicine, Humans, Pharmacology (medical), Treatment Failure, 030212 general & internal medicine, Adverse effect, Aged, Retrospective Studies, Aged, 80 and over, Tumor Necrosis Factor-alpha, business.industry, Inflammatory Bowel Disease, Adalimumab, Age Factors, Antibodies, Monoclonal, Retrospective cohort study, Middle Aged, Inflammatory Bowel Diseases, medicine.disease, Ulcerative colitis, Infliximab, Sicilian Network for Inflammatory Bowel Diseases (SN-IBD), Withholding Treatment, Concomitant, Female, Geriatrics and Gerontology, business, 030217 neurology & neurosurgery, Cohort study
Abstract

BACKGROUND AND OBJECTIVE: Older people with inflammatory bowel disease (IBD) appear to have a lower response to anti-tumour necrosis factor (TNF) therapy, with more frequent complications than younger patients. The objective of this study was to assess persistence on therapy and the safety of anti-TNF therapy in older patients (aged ≥ 60 years). METHODS: We retrospectively reviewed the database of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD), extracting data regarding IBD patients aged ≥ 60 years and controls

Published
2020

4. Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

Author

Fernando Rizzello, Antonio Ferronato, Luisa Moser, Stefano Festa, Chiara Ricci, Giorgia Bodini, Silvia Mazzuoli, Giuseppe Privitera, Francesca Rogai, R. Sablich, Angela Variola, Claudio Camillo Cortelezzi, Daniela Pugliese, Laurino Grossi, Maria Cappello, Lucrezia Laterza, Anna Viola, Maria Di Girolamo, Fabrizio Bossa, Giammarco Mocci, Antonino Carlo Privitera, Mariabeatrice Principi, Marco Daperno, Simone Saibeni, Rocco Spagnuolo, Mariangela Allocca, Greta Lorenzon, Sara Traini, Alessandro Armuzzi, G. Tapete, Filippo Mocciaro, and Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Di Girolamo M, Grossi L, Mocci G, Rizzi C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, naïve, Golimumab, Persistence (computer science), 03 medical and health sciences, Young Adult, 0302 clinical medicine, remission, Gastrointestinal Agents, Internal medicine, medicine, Humans, Prospective Studies, Aged, Retrospective Studies, ulcerative colitis, business.industry, Tumor Necrosis Factor-alpha, Inflammatory Bowel Disease, Gastroenterology, Antibodies, Monoclonal, persistence, Middle Aged, medicine.disease, Ulcerative colitis, Oncology, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Colitis, Ulcerative, Female, Original Article, business, medicine.drug, Follow-Up Studies, IBD Ulcerative colitis Golimumab TNF-inhibitors
Abstract

Background Few data exist regarding the long‐term effectiveness of golimumab in ulcerative colitis. No data have been reported on real‐world continuous clinical response. Objective This study aimed to describe the long‐term outcomes in a large cohort of patients on golimumab who had ulcerative colitis. Methods Consecutive patients with active ulcerative colitis, started on golimumab, were enrolled and prospectively followed up. The primary end point was to evaluate the long‐term persistence on golimumab therapy. Results A total of 173 patients with ulcerative colitis were studied. Of these, 79.2% were steroid dependent, and 46.3% were naïve to anti‐tumour necrosis factor alpha agents. The median duration of golimumab therapy was 52 weeks (range: 4–142 weeks). The cumulative probability of maintaining golimumab treatment was 47.3% and 22.5% at 54 and 108 weeks, respectively. Biological‐naïve status (odds ratio [OR] = 3.02, 95% confidence interval [CI]: 1.44–6.29; p = 0.003) and being able to discontinue steroids at Week 8 (OR = 3.32, 95% CI: 1.34–8.30; p = 0.010) and Week 14 (OR = 2.94, 95% CI: 1.08–8.02; p = 0.036) were associated with longer persistence on therapy. At Week 54, 65/124 (52.4%) postinduction responders were in continuous clinical response. A continuous clinical response was associated with a lower likelihood of golimumab discontinuation throughout the subsequent year of therapy (p

Published
2021

5. Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis

Author

Antonino Carlo Privitera, Antonio Rispo, C. Ferracane, Maria Cappello, Raffaele Melina, Francesco William Guglielmi, Angelo Andriulli, Rocco Spagnuolo, Fabrizio Bossa, Giuseppe Costantino, M. Mendolaro, Mariabeatrice Principi, Agnese Miranda, Pietro Paese, Alessandro Azzarone, Ladislava Sebkova, Silvia Mazzuoli, Olga Maria Nardone, R. Clemente, Antonio Tursi, Marco Romano, M. Patturelli, A. Lauria, Endrit Shahini, C. Ricciardelli, Caterina Sgarro, L. Fanigliulo, Laurino Grossi, Gabriele Riegler, Walter Fries, Giuseppe Pranzo, Nello Buccianti, Gaetano Inserra, Giuseppe Biscaglia, Maria Rosa Valvano, Bossa, F, Biscaglia, G, Valvano, Mr, Costantino, G, Lauria, A, Clemente, R, Ferracane, C, Shahini, E, Mendolaro, M, Grossi, L, Mazzuoli, S, Rispo, A, Pranzo, G, Sebkova, L, Tursi, A, Miranda, A, Patturelli, M, Spagnuolo, R, Ricciardelli, C, Sgarro, C, Paese, P, Inserra, G, Azzarone, A, Nardone, O, Fries, W, Buccianti, N, Privitera, Ac, Principi, Mb, Cappello, M, Guglielmi, Fw, Romano, M, Riegler, G, Fanigliulo, L, Melina, R, and Andriulli, A.

Subjects
Adult, Male, medicine.medical_specialty, Multivariate analysis, Physiology, Biologics, Inflammatory bowel disease, Golimumab, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Autoinjector, Internal medicine, Medicine, Humans, Adverse effect, Dose-Response Relationship, Drug, business.industry, Gastroenterology, Anti-TNF-alpha, Ulcerative colitis, Antibodies, Monoclonal, Hepatology, Middle Aged, medicine.disease, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Colitis, Ulcerative, Female, Calprotectin, business, medicine.drug
Abstract

Golimumab is a new anti-TNF-alpha monoclonal antibody for patients with ulcerative colitis. To assess the short- and long-term effectiveness and safety of golimumab in daily clinical practice and to identify predictors of response. Consecutive patients treated with golimumab in 22 Italian centers were enrolled. Clinical, laboratory, and endoscopic data were prospectively collected before and during treatment. A subgroup of patients completed a questionnaire to assess personal satisfaction with a golimumab autoinjector system. A total of 196 patients were included. After 3 months, 130 patients were responders (66.3%) and showed significant reductions in mean partial, total, and endoscopic Mayo scores and in mean ESR, C-reactive protein, and fecal calprotectin levels (p

Published
2019

6. Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study

Author

Federica Furfaro, Vito Annese, Alessandro Armuzzi, Walter Fries, Daniela Pugliese, Gaetano Inserra, Maria Cappello, I. Frankovic, Antonino Carlo Privitera, Francesca Calella, Natalia Manetti, Francesco Manguso, Silvio Danese, Flavio Caprioli, Fabrizio Bossa, Matilde Rea, Angela Alibrandi, Laura Cantoro, Giuseppe Scalisi, Giovanni Casella, Stefania Orlando, Sandro Ardizzone, Gionata Fiorino, Anna Viola, Giammarco Mocci, Mariabeatrice Principi, R. Bringiotti, Anna Kohn, Fabiana Castiglione, R. Monterubbianesi, Renata D'Incà, Annalisa Aratari, L. Samperi, Claudio Papi, Simone Saibeni, Viola, A, Monterubbianesi, R, Scalisi, G, Furfaro, F, Rea, M, Saibeni, S, Aratari, A, Bringiotti, R, Casella, G, Cantoro, L, Frankovic, I, Calella, F, Pugliese, D, Orlando, S, Samperi, L, Cappello, M, Mocci, G, Manetti, N, Annese, V, Privitera, Ac, Inserra, G, Caprioli, F, D'Inca, R, Principi, M, Papi, C, Castiglione, F, Danese, S, Ardizzone, S, Bossa, F, Kohn, A, Manguso, F, Alibrandi, A, Fiorino, G, Armuzzi, A, Fries, W, Viola, A., Monterubbianesi, R., Scalisi, G., Furfaro, F., Rea, M., Saibeni, S., Aratari, A., Bringiotti, R., Casella, G., Cantoro, L., Frankovic, I., Calella, F., Pugliese, D., Orlando, S., Samperi, L., Cappello, M., Mocci, G., Manetti, N., Annese, V., Privitera, A. C., Inserra, G., Caprioli, F., D'Inca, R., Principi, M., Papi, C., Castiglione, F., Danese, S., Ardizzone, S., Bossa, F., Kohn, A., Manguso, F., Alibrandi, A., Fiorino, G., Armuzzi, A., and Fries, W.

Subjects
Male, Disease, Constriction, Pathologic, tumours, Inflammatory bowel disease, Late Onset Disorders, Cohort Studies, surgery, 0302 clinical medicine, Crohn Disease, Medicine, Young adult, Digestive System Surgical Procedures, Crohn's disease, Gastroenterology, Ileitis, Middle Aged, Colitis, Italy, 030220 oncology & carcinogenesis, outcome, 030211 gastroenterology & hepatology, Female, Colorectal Neoplasms, Cohort study, steroids, Adult, medicine.medical_specialty, Adolescent, comorbidities, elderly, 03 medical and health sciences, Young Adult, Internal medicine, Intestinal Fistula, Humans, Immunologic Factors, Glucocorticoids, Aged, Retrospective Studies, Polypharmacy, Hepatology, business.industry, thiopurines, Retrospective cohort study, medicine.disease, Tumor Necrosis Factor Inhibitors, business
Abstract

BACKGROUND Disease phenotype and outcome of late-onset Crohn's disease are still poorly defined. METHODS In this Italian nationwide multicentre retrospective study, patients diagnosed ≥65 years (late-onset) were compared with young adult-onset with 16-39 years and adult-onset Crohn's disease 40-64 years. Data were collected for 3 years following diagnosis. RESULTS A total of 631 patients (late-onset 153, adult-onset 161, young adult-onset 317) were included. Colonic disease was more frequent in late-onset (P < 0005), stenosing behaviour was more frequent than in adult-onset (P < 0003), but fistulising disease was uncommon. Surgery rates were not different between the three age groups. Systemic steroids were prescribed more frequently in young adult-onset in the first year, but low bioavailability steroids were used more frequently in late-onset in the first 2 years after diagnosis (P < 0.036, P < 0.041, respectively). The use of immunomodulators and anti-TNF's even in patients with more complicated disease, that is, B2 or B3 behaviour (Montreal classification), remained significantly inferior (P < 0.0001) in late-onset compared to young adult-onset. Age at diagnosis, Charlson comorbidity index, and steroid used in the first year were negatively associated with the use of immunomodulators and biologics. Comorbidities, related medications and hospitalizations were more frequent in late-onset. Polypharmacy was present in 56% of elderly Crohn's disease patients. CONCLUSION Thirty-two percent of late-onset Crohn's disease presented with complicated disease behaviour. Despite a comparable use of steroids and surgery, immunomodulators and biologics were used in a small number of patients.

Published
2019

7. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis

Author

Maria Cappello, Mario Cottone, R. Orlando, A. Magnano, Gaetano Inserra, Sara Renna, Antonio Carroccio, Antonino Carlo Privitera, M. Mendolaro, Ambrogio Orlando, D. Pluchino, Filippo Mocciaro, Fabio Salvatore Macaluso, Walter Fries, Marco Ventimiglia, G. Scarpulla, Roberto Di Mitri, S. Siringo, C. Ferracane, V. Pisana, S. Garufi, and Renna S, Mocciaro F, Ventimiglia M, Orlando R, Macaluso FS, Cappello M, Fries W, Mendolaro M, Privitera AC, Ferracane C, Pisana V, Magnano A, Pluchino D, Inserra G, Scarpulla G, Garufi S, Carroccio A, Siringo S, Di Mitri R, Cottone M, Orlando A.

Subjects
musculoskeletal diseases, Moderate to severe, Adult, Male, medicine.medical_specialty, Settore MED/09 - Medicina Interna, Biologic, Disease duration, Adalimumab, Biologics, Golimumab, Ulcerative colitis, Antibodies, Monoclonal, Colitis, Ulcerative, Female, Humans, Italy, Logistic Models, Middle Aged, Propensity Score, Proportional Hazards Models, Severity of Illness Index, Treatment Outcome, Tumor Necrosis Factor-alpha, Ulcerative, Treatment failure, Antibodies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Monoclonal, medicine, skin and connective tissue diseases, Hepatology, Gastroenterology, business.industry, medicine.disease, Colitis, humanities, 030220 oncology & carcinogenesis, Propensity score matching, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

Background Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in golimumab patients (p = 0.008) at the end of follow up. These data were confirmed by propensity score analysis. A further analysis considering adalimumab optimization as treatment failure showed that the difference between adalimumab and golimumab was not significant. Conclusion Adalimumab and golimumab are effective in the treatment of ulcerative colitis. Adalimumab seems to be more effective than golimumab. This difference is probably affected by the impossibility of golimumab to be optimized in Italy while adalimumab is.

Published
2018

8. Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD 'AGED study'

Author

Gionata Fiorino, Anna Viola, Maria Cappello, Vito Annese, Anna Kohn, R. Monterubbianesi, Renata D'Incà, Daniela Pugliese, Natalia Manetti, Fabrizio Bossa, Claudio Papi, L. Samperi, Gaetano Inserra, Francesca Calella, Mariabeatrice Principi, Giammarco Mocci, Giovanni Casella, Antonella Contaldo, Alessandro Armuzzi, Fabiana Castiglione, Antonino Carlo Privitera, Andrea Magarotto, Francesco Manguso, Annalisa Aratari, Stefanos Bonovas, Angela Alibrandi, Federica Furfaro, Flavio Caprioli, Matilde Rea, Laura Cantoro, Silvio Danese, Giuseppe Scalisi, Sandro Ardizzone, Simone Saibeni, Walter Fries, I. Frankovic, Fries, Walter, Viola, Anna, Manetti, Natalia, Frankovic, Iri, Pugliese, Daniela, Monterubbianesi, Rita, Scalisi, Giuseppe, Aratari, Annalisa, Cantoro, Laura, Cappello, Maria, Samperi, Leonardo, Saibeni, Simone, Casella, Giovanni, Mocci, Giammarco, Rea, Matilde, Furfaro, Federica, Contaldo, Antonella, Magarotto, Andrea, Calella, Francesca, Manguso, Francesco, Inserra, Gaetano, Privitera, Antonino C, Principi, Mariabeatrice, Castiglione, Fabiana, Caprioli, Flavio, Ardizzone, Sandro, Danese, Silvio, Papi, Claudio, Bossa, Fabrizio, Kohn, Anna, Armuzzi, Alessandro, D'Incà, Renata, Annese, Vito, Alibrandi, Angela, Bonovas, Stefano, Fiorino, Gionata, Fries, W, Viola, A, Manetti, N, Frankovic, I, Pugliese, D, Monterubbianesi, R, Scalisi, G, Aratari, A, Cantoro, L, Cappello, M, Samperi, L, Saibeni, S, Casella, G, Mocci, G, Rea, M, Furfaro, F, Contaldo, A, Magarotto, A, Calella, F, Manguso, F, Inserra, G, Privitera, Ac, Principi, M, Castiglionen, F, Caprioli, F, Ardizzone, S, Danese, S, Papi, C, Bossa, F, Kohn, A, Armuzzi, A, D'Inca, R, Annese, V, Alibrandi, A, Bonovas, S, and Fiorino, G

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Disease, Gastroenterology, Severity of Illness Index, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Risk Factors, Internal medicine, Severity of illness, medicine, Humans, Immunologic Factors, Young adult, Age of Onset, Steroid, Thiopurines, Colectomy, Outcome, Tumors, Aged, Retrospective Studies, Steroids, Surgery, Hepatology, Thiopurine, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Ulcerative colitis, Natural history, Logistic Models, Italy, Disease Presentation, 030220 oncology & carcinogenesis, Disease Progression, 030211 gastroenterology & hepatology, Colitis, Ulcerative, Female, Age of onset, business
Abstract

Background: Late-onset UC represents an important issue for the near future, but its outcomes and relative therapeutic strategies are yet poorly studied. Aim: To better define the natural history of late-onset ulcerative colitis. Methods: In a multicenter retrospective study, we investigated the disease presentation and course in the first 3 years in 1091 UC patients divided into 3 age-groups: diagnosis >65 years, 40-64 years, and

Published
2017

9. Risk factor analysis for therapy related adverse events and infections in elder patients with Inflammatory Bowel Disease; An analysis from the IG-IBD aged study

Author

Ferrara, A., Viola, A., Mannetti, N., Coppola, M., Frankovic, I., Monterubbianesi, R., Pugliese, D., Aratri, A., Cappello, M., Costantino, G., Saibeni, S., Principi, M., Furfaro, F., Fiorino, G., Mocci, G., Castiglione, F., Scalisi, G., Callela, F., Magarotto, A., Caprioli, F., Casella, G., Samperi, L., Privitera, A. C., Inserra, G., Danese, S., Ardizzone, S., Papi, C., Armuzzi, A., Kohn, A., Bossa, F., Renata D'Incà, Annese, V., Alibrandi, A., Fries, W., Ferrara, A, Viola, A, Mannetti, N, Coppola, M, Frankovic, I, Monterubbianesi, R, Pugliese, D, Aratri, A, Cappello, M, Costantino, G, Saibeni, S, Principi, M, Furfaro, F, Fiorino, G, Mocci, G, Castiglione, F, Scalisi, G, Callela, F, Magarotto, A, Caprioli, F, Casella, G, Samperi, L, Privitera, Ac, Inserra, G, Danese, S, Ardizzone, S, Papi, C, Armuzzi, A, Kohn, A, Bossa, F, D'Inca, R, Annese, V, Alibrandi, A, Fries, W, Manetti, N, Aratari, A, Cantoro, L, and Calella, F

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results